Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

NDAQ:AUPH - Post by User

Aurinia Pharmaceuticals Inc > Buyout?

<< Previous

Bullboard Posts

Next >>

Comment by TimeScapeon Oct 26, 2021 12:51am

143 Views

Post# 34048217

RE:RE:Buyout?

The AUPH stock price was $22 before the rumour came out on Friday. A 50% premium would get get it to $33. I doubt an offer would be for much more than that. Maybe $35. AUPH hasn't got much of a pipeline. The lupus nephritis indication is excellent, and they should get a big market share, but it's not a huge market.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale